Abstract
e16036Background: Data supporting the benefit from second-line chemotherapy in patients with metastatic urothelial carcinoma (UC) is limited. Furthermore, factors predicting survival following prog...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
